216 related articles for article (PubMed ID: 32415507)
1. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
[TBL] [Abstract][Full Text] [Related]
2. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine.
Ando M; Miyazaki E; Yamasue M; Sadamura Y; Ishii T; Takenaka R; Ito T; Nureki S; Kumamoto T
Clin Rheumatol; 2010 Apr; 29(4):443-5. PubMed ID: 20130943
[TBL] [Abstract][Full Text] [Related]
4. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
5. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review.
Lai KC; Hsiao YH; Chen SC
Front Immunol; 2022; 13():994064. PubMed ID: 36119082
[TBL] [Abstract][Full Text] [Related]
6. Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report.
Miao K; Xu Y; Xu W; Zhang Y; Xu Y; Tian X; Zhang L
Thorac Cancer; 2021 Aug; 12(15):2214-2216. PubMed ID: 34145962
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O
Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683
[TBL] [Abstract][Full Text] [Related]
8. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
Nobashi TW; Nishimoto Y; Kawata Y; Yutani H; Nakamura M; Tsuji Y; Yoshida A; Sugimoto A; Yamamoto T; Alam IS; Noma S
Br J Radiol; 2020 Nov; 93(1115):20200409. PubMed ID: 32783627
[TBL] [Abstract][Full Text] [Related]
9. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
10. Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab.
Sawai Y; Katsuya Y; Shinozaki-Ushiku A; Iwasaki A; Fukayama M; Watanabe K; Nagase T
Drug Discov Ther; 2019 Jul; 13(3):164-167. PubMed ID: 31257354
[TBL] [Abstract][Full Text] [Related]
11. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
12. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
14. Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report.
Yamada K; Asai K; Okamoto A; Watanabe T; Kanazawa H; Ohata M; Ohsawa M; Hirata K
BMC Res Notes; 2018 Jan; 11(1):34. PubMed ID: 29338781
[TBL] [Abstract][Full Text] [Related]
15. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
Andersson NW; Zachariae C; Simonsen AB
Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
[No Abstract] [Full Text] [Related]
16. Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.
Larsen BT; Chae JM; Dixit AS; Hartman TE; Peikert T; Roden AC
Am J Surg Pathol; 2019 Oct; 43(10):1331-1340. PubMed ID: 31162288
[TBL] [Abstract][Full Text] [Related]
17. Chronic immune checkpoint inhibitor pneumonitis.
Naidoo J; Cottrell TR; Lipson EJ; Forde PM; Illei PB; Yarmus LB; Voong KR; Feller-Kopman D; Lee H; Riemer J; Wang D; Taube JM; Brahmer JR; Lin CT; Danoff SK; D'Alessio FR; Suresh K
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554618
[TBL] [Abstract][Full Text] [Related]
18. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
19. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
[No Abstract] [Full Text] [Related]
20. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Rickard F; Hyams C; Low AT
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29735504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
